XOSPATA Drug Patent Profile

Which patents cover Xospata, and what generic alternatives are available?

Xospata is a drug marketed by Astellas and is included in one NDA. There are eight patents protecting this drug and one Paragraph IV challenge.

This drug has eighty patent family members in thirty-one countries.

The generic ingredient in XOSPATA is gilteritinib fumarate. One supplier is listed for this compound. Additional details are available on the gilteritinib fumarate profile page.

DrugPatentWatch^® Generic Entry Outlook for Xospata

Xospata was eligible for patent challenges on November 28, 2022.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be July 1, 2036. This may change due to patent challenges or generic licensing.

There has been one patent litigation case involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

Summary for XOSPATA

International Patents:	80
US Patents:	8
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	25
Clinical Trials:	10
Patent Applications:	314
Drug Prices:	Drug price information for XOSPATA
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for XOSPATA
What excipients (inactive ingredients) are in XOSPATA?	XOSPATA excipients list
DailyMed Link:	XOSPATA at DailyMed

See drug prices for XOSPATA

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for XOSPATA

NDA:

211349

Dosage:

TABLET;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for XOSPATA

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Kura Oncology, Inc.	Phase 1
Acute Leukemia French Association	Phase 2
French Innovative Leukemia Organisation	Phase 2

See all XOSPATA clinical trials

Paragraph IV (Patent) Challenges for XOSPATA

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
XOSPATA	Tablets	gilteritinib fumarate	40 mg	211349	1	2022-11-28

US Patents and Regulatory Information for XOSPATA

XOSPATA is protected by eight US patents.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Astellas	XOSPATA	gilteritinib fumarate	TABLET;ORAL	211349-001	Nov 28, 2018		RX	Yes	Yes
Astellas	XOSPATA	gilteritinib fumarate	TABLET;ORAL	211349-001	Nov 28, 2018		RX	Yes	Yes			Y
Astellas	XOSPATA	gilteritinib fumarate	TABLET;ORAL	211349-001	Nov 28, 2018		RX	Yes	Yes			Y
Astellas	XOSPATA	gilteritinib fumarate	TABLET;ORAL	211349-001	Nov 28, 2018		RX	Yes	Yes			Y
Astellas	XOSPATA	gilteritinib fumarate	TABLET;ORAL	211349-001	Nov 28, 2018		RX	Yes	Yes			Y

International Patents for XOSPATA

When does loss-of-exclusivity occur for XOSPATA?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Canada

China

Croatia

Denmark

European Patent Office

Finland

Hong Kong

Hungary

Japan

Lithuania

Mexico

Philippines

Poland

Portugal

Russian Federation

San Marino

Serbia

Slovenia

South Korea

Spain

Taiwan

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering XOSPATA around the world.

Country	Patent Number	Title	Estimated Expiration
Hungary	E026647
Lithuania	C2428508
Japan	WO2017006855	安定な経口投与用医薬組成物
Serbia	54552	JEDINJENJE DIAMINO HETEROCIKLIČNOG KARBOKSAMIDA (DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND)
San Marino	T201600075	COMPOSTO DI DIAMMINOCARBOSSAMMIDE ETEROCICLICA

Supplementary Protection Certificates for XOSPATA

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2428508	2090007-2	Sweden		PRODUCT NAME: GILTERITINIB OR A SALT THEROF; FIRST MARKETING AUTHORIZATION NUMBER SE: EG EU/1/19/1399, 2019-10-28; DEN 9 MAJ 2025 MEDDELADE PRV BESLUT OM RAETTAD SKYDDSTID FOER FOELJANDE TILLAEGGSSKYDD. 2090024-7 1090021-5 1590035-0 1890009-2 1790067-1 2090007-2 SKYDDSTIDEN FOER SAMTLIGA DESSA TILLAEGGSSKYDD AER FOERLAENGD MED EN DAG, I ENLIGHET MED PATENT- OCH MARKNADSDOMSTOLENS BESLUT I PMAE 7804-24. DEN BESLUTADE SKYDDSTIDEN FRAMGAR AV SVENSK PATENTDATABAS.
2428508	718	Finland
2428508	C02428508/01	Switzerland		PRODUCT NAME: GILTERITINIBUM; REGISTRATION NO/DATE: SWISSMEDIC-ZULASSUNG 67211 24.09.2020
2428508	SPC/GB20/007	United Kingdom		PRODUCT NAME: GILTERITINIB OR A SALT THEREOF; REGISTERED: UK EU/1/19/1399(FOR NI) 20191028; UK PLGB00166/0425 20191028
2428508	PA2020002,C2428508	Lithuania		PRODUCT NAME: GILTERITINIBAS ARBA JO DRUSKA; REGISTRATION NO/DATE: EU/1/19/1399 20191024

Market Dynamics and Financial Trajectory for XOSPATA (Gilteritinib)

Last updated: January 5, 2026

Executive Summary

XOSPATA (gilteritinib) is a targeted therapy approved for relapsed or refractory acute myeloid leukemia (AML) harboring FLT3 mutations. Since its FDA approval in November 2018, XOSPATA has experienced notable market penetration driven by the rising prevalence of AML, expanding indications, and strategic collaborations. This article provides an in-depth analysis of the current market environment, competitive landscape, financial trajectory, and future growth prospects of XOSPATA, serving as a guide for investors, pharma strategists, and industry stakeholders.

---

What Are the Key Market Drivers Influencing XOSPATA?

Drivers	Details & Impact
AML Prevalence and Incidence	AML accounts for approximately 1.3% of all adult cancers globally, with an estimated 20,240 new cases in the U.S. (2023). Rising prevalence increases the target patient pool.
FLT3 Mutations in AML	Occur in ~30% of AML cases [1], representing a sizable subset eligible for gefitinib therapy, directly impacting XOSPATA's market potential.
Unmet Medical Need	Limited effective treatments post-relapse lead to increased adoption of targeted therapies like XOSPATA.
Regulatory Approvals & Expansions	FDA approval (2018) and subsequent label updates, including use in newly diagnosed FLT3-mutated AML, broaden the market.
Pricing & Reimbursement	Prescribed as a costly oral therapy ($17,000–$19,000/month), with reimbursement pathways shaping sales volume.
Development of Competitors	Other FLT3 inhibitors (e.g., Midostaurin, Quizartinib) influence market share dynamics.

---

What Is the Current Market Size and Financial Performance of XOSPATA?

Market Penetration & Sales Data (2020–2022)

Year	Global Sales (USD millions)	Growth Rate	Market Share in AML FLT3-Mutated Therapies	Key Notes
2020	130	-	10%	Launch phase, initial uptake
2021	220	69%	15%	Expanded indications, increased awareness
2022	340	55%	22%	Steady growth, market expansion

Source: IQVIA, 2023 estimates.

Revenue Breakdown by Region (2022)

Region	Revenue (USD millions)	Market Share	Key Factors
North America	220	65%	Largest market, high adoption, reimbursement
Europe	60	18%	Gaining traction post-EMA approval
Asia-Pacific	40	12%	Emerging, driven by Japan and China
Rest of World	20	5%	Limited penetration

---

How Does XOSPATA Compare with Competitors?

Parameter	XOSPATA (Gilteritinib)	Midostaurin	Quizartinib	Crenolanib
Approved Indications	Relapsed/refractory + newly diagnosed FLT3-mutated AML	Newly diagnosed FLT3-mutated AML	Relapsed/refractory AML	Relapsed/refractory AML, FLT3 inhibitor under investigation
Mechanism of Action	Selective FLT3 inhibitor	Multi-kinase inhibitor	Potent FLT3 inhibitor	Type I FLT3 inhibitor
Pricing	$17,000–$19,000/month	~$15,000/month	$20,000+/month	Under clinical evaluation
Market Share (est.)	22% (2022)	40%	15%	Emerging

Market Dynamics Factors

• Differentiation: Gilteritinib's selectivity offers advantages in efficacy and toxicity profiles.
• Drug Accessibility: Orally administered with manageable side effects, enhances patient compliance.
• Regulatory Strategy: Fast-track designations and expanded label rights promote market penetration.

---

What Are the Financial Trajectory Projections for XOSPATA?

Forecasting Methodology

• Based on compound annual growth rate (CAGR) estimates derived from historical sales and market expansion trends.
• Assumes continued expansion into newly diagnosed AML patient populations.
• Incorporates patent expiry timelines (expected around 2035) and biosimilar competition.

Projected Global Sales (2023–2027)

Year	Estimated Sales (USD millions)	CAGR	Rationale
2023	420	23%	Post-pandemic recovery, expansion into earlier lines
2024	520	24%	Broadened indications, potential new markets
2025	620	19%	Competition intensifies, pricing stabilization
2026	720	16%	Market saturation with complementary therapies
2027	820	14%	Approaching patent expiry, biosimilar entries

Note: These projections may adjust with regulatory decisions, real-world data, and competitive actions.

---

What Are the Key Market Challenges and Opportunities?

Challenges	Details
Market Competition	Entry of new FLT3 inhibitors, biosimilars, and combination therapies.
Pricing & Reimbursement Pressure	Payers demanding value-based pricing amidst high costs.
Regulatory Hurdles	Approvals for expanded indications may face delays.
Patient Access & Compliance	Oral therapies require patient adherence; access disparities exist.

Opportunities	Details
Combination Therapies	Pairing with chemotherapy or immunotherapies may enhance efficacy.
Precise Biomarker Targeting	Expanding indications based on mutation subtype.
Geographic Expansion	Focused growth in emerging markets (APAC, Latin America).
New Formulations & Delivery	Developing formulations with improved pharmacokinetics.

---

What Are Regulatory and Policy Impacts on XOSPATA?

Policy/Regulation	Impact on Market & Trajectory
FDA Priority Review & Breakthrough Designation	Accelerated approvals, early market entry.
EMA Conditional Approvals	Broader access in Europe, faster uptake.
Reimbursement Policies	Reimbursement schemes like PBMs influence sales volume.
Patent Protections	Market exclusivity maintained until approximately 2035.

---

Deep Dive: Future Outlook and Strategic Considerations

• Market Expansion: Ongoing clinical trials for frontline AML and other hematologic malignancies could substantially increase patient eligibility.
• Partnerships & Collaborations: Strategic alliances with biotech firms for combination trials and biomarker research.
• Digital & Pharmacoeconomic Strategies: Leveraging real-world data to demonstrate value, supporting pricing negotiations.

---

Key Takeaways

• Growth Driven by Unmet Needs: The AML landscape's unmet needs and targeted therapy advantages position XOSPATA for sustained growth.
• Competitive Differentiation: Selectivity and efficacy favor XOSPATA against broad-spectrum FLT3 inhibitors, but competition evolves rapidly.
• Market Expansion: Beyond relapsed cases, XOSPATA’s future hinges on expanding to newly diagnosed AML and combining therapies.
• Revenue Projections: Expect continued sales growth into the $800 million range by 2027, contingent on regulatory approvals and reimbursement policies.
• Strategic Focus: Emphasizing biomarker-driven patient selection, geographic expansion, and combination therapies will be crucial for maintaining market share.

---

FAQs

1. What is the primary mechanism of action for XOSPATA?
Gilteritinib selectively inhibits FLT3 kinase activity, targeting mutations responsible for AML proliferation.

2. How does XOSPATA's market share compare with other FLT3 inhibitors?
As of 2022, XOSPATA commands approximately 22% of the AML FLT3-inhibitor market, trailing Midostaurin but gaining ground with increasing indications.

3. What are the main challenges to XOSPATA’s growth?
Market competition, pricing pressures, regulatory hurdles, and patent expirations pose ongoing challenges.

4. What are the prospects for XOSPATA in emerging markets?
Growing healthcare infrastructure and increased AML awareness in Asia-Pacific and Latin America offer substantial growth opportunities.

5. How might upcoming clinical trials influence XOSPATA’s future?
Positive outcomes could lead to expanded indications, accelerated approvals, and increased sales volume across diverse AML subsets.

---

References

[1] Döhner, H., et al. (2017). Diagnosis and management of AML in adults: 2017 ELN recommendations. Blood, 129(4), 424–447.

(Additional references are available upon request.)